4
Changes in Ownership
Denali Therapeutics Inc. Filed Acc 0001209191-21-016855
Director sold 100,000 shares at an average $66.22 ($6,622,207)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Tessier-Lavigne Marc Director | 2021-03-01 | Sale | −18,770 | $64.36 | $1,208,056 | 2,723,526 | D |
| Tessier-Lavigne Marc Director | 2021-03-01 | Sale | −37,445 | $65.63 | $2,457,665 | 2,686,081 | D |
| Tessier-Lavigne Marc Director | 2021-03-01 | Sale | −18,316 | $66.55 | $1,219,003 | 2,667,765 | D |
| Tessier-Lavigne Marc Director | 2021-03-01 | Sale | −14,945 | $67.57 | $1,009,834 | 2,652,820 | D |
| Tessier-Lavigne Marc Director | 2021-03-01 | Sale | −6,011 | $68.50 | $411,778 | 2,646,809 | D |
| Tessier-Lavigne Marc Director | 2021-03-01 | Sale | −3,482 | $69.59 | $242,309 | 2,643,327 | D |
| Tessier-Lavigne Marc Director | 2021-03-01 | Sale | −1,031 | $71.35 | $73,563 | 2,642,296 | D |
| Open-market sales · 100,000 sh · avg $66.22 · $6,622,207 | |||||||
Loading xslF345X03/doc4.xml…